RE 201 - CAS 254740-64-2
Sparsentan, also known as RE-021, PS433540 and DARA-a, is a Dual angiotensin II and endothelin A receptor antagonist. Retrophin intends to develop RE-021 for orphan indications of severe kidney diseases including Focal Segmental Glomerulosclerosis (FSGS) as well as conduct proof-of-concept studies in resistant hypertension and diabetic nephropathy. RE-021, with its unique dual blockade of angiotensin and endothelin receptors, is expected to provide meaningful clinical benefits in mitigating proteinuria in indications where there are no approved therapies.
* For research use only. Not for human or veterinary use.
|Target:||Dual angiotensin II and endothelin A receptor antagonist|
|Storage||Store at -20°C|